-
公开(公告)号:US20240069042A1
公开(公告)日:2024-02-29
申请号:US18387593
申请日:2023-11-07
发明人: Xin Huang , Yihan Li , James Doecke , Michal Eisenbach-Schwartz , Baijun Gu
CPC分类号: G01N33/6896 , G01N33/582 , G01N2800/2821
摘要: Compositions and kits for diagnosing and prognosing Alzheimer's Disease (AD) in a human patient include a binding agent such as a monoclonal antibody for a biomarker conjugated to a detectable moiety such as a fluorophore, wherein the biomarker is chosen from CD11c, CD59, CD91, and CD163 and other phagocytosis-related molecules. Further compositions and kits employ panels of fluorophore-conjugated monoclonal antibodies for biomarkers including scavenger receptors. Methods for determining the relative expression of biomarkers, diagnosing AD, and determining the efficacy of AD therapeutic candidates such as phagocytosis-promoting agents and scavenger receptor agonists also appear.
-
公开(公告)号:US20230054073A1
公开(公告)日:2023-02-23
申请号:US17882671
申请日:2022-08-08
申请人: NEUROQUEST LTD.
发明人: Xin Huang , Yihan Li , Christopher Fowler , James Doecke , Colin L. Masters , Baijun Gu
摘要: Compositions and kits for diagnosing and prognosing Alzheimer's Disease (AD) in a human patient include a binding agent such as a monoclonal antibody for a biomarker conjugated to a detectable moiety such as a fluorophore, wherein the biomarker is chosen from CD163, CD91, CD59, MerTK and other phagocytosis-related molecules. Further compositions and kits employ panels of fluorophore-conjugated monoclonal antibodies for biomarkers including scavenger receptors. Methods for determining the relative expression of biomarkers, diagnosing AD, and determining the efficacy of AD therapeutic candidates such as phagocytosis-promoting agents and scavenger receptor agonists also appear.
-